BACKGROUND: Previous studies have reported additional cancers associated with BRCA mutations; however, the type, magnitude of risk, and sex differences remain to be clarified. The purpose of this study was to evaluate the incidence of cancers other than breast and ovarian cancer in known mutation carriers. METHODS: An institutional review board-approved study identified 1072 patients who had genetic counseling at the authors' institution and tested positive for a deleterious BRCA mutation. The expected number of cancer cases was calculated from the number of individuals in the study sample multiplied by the cancer incidence rates for the general population. The expected and observed numbers of cases were calculated in 5-year intervals to accommodate different age-related incidence rates. Standardized incidence ratios (SIRs) for each cancer type were calculated. RESULTS: Among the 1072 mutation carriers, 1177 cancers of 30 different cancer types were identified. Individuals with a BRCA1 mutation did not have a significant increase in cancers other than breast and ovarian cancer; however, a trend in melanoma was observed. Individuals with a BRCA2 mutation had significantly higher numbers of observed cases versus expected cases for pancreatic cancer in both men and women (SIR, 21.7; 95% confidence interval [CI], 13.1-34.0; P < .001) and for prostate cancer in men (SIR, 4.9; 95% CI, 2.0-10.1; P = .002). CONCLUSIONS: The results of this study uphold the current recommendations for hereditary breast and ovarian cancer screening of cancers other than breast and ovarian cancer by the National Comprehensive Cancer Network. Larger cohorts and collaborations are needed to further verify these findings.
BACKGROUND: Previous studies have reported additional cancers associated with BRCA mutations; however, the type, magnitude of risk, and sex differences remain to be clarified. The purpose of this study was to evaluate the incidence of cancers other than breast and ovarian cancer in known mutation carriers. METHODS: An institutional review board-approved study identified 1072 patients who had genetic counseling at the authors' institution and tested positive for a deleterious BRCA mutation. The expected number of cancer cases was calculated from the number of individuals in the study sample multiplied by the cancer incidence rates for the general population. The expected and observed numbers of cases were calculated in 5-year intervals to accommodate different age-related incidence rates. Standardized incidence ratios (SIRs) for each cancer type were calculated. RESULTS: Among the 1072 mutation carriers, 1177 cancers of 30 different cancer types were identified. Individuals with a BRCA1 mutation did not have a significant increase in cancers other than breast and ovarian cancer; however, a trend in melanoma was observed. Individuals with a BRCA2 mutation had significantly higher numbers of observed cases versus expected cases for pancreatic cancer in both men and women (SIR, 21.7; 95% confidence interval [CI], 13.1-34.0; P < .001) and for prostate cancer in men (SIR, 4.9; 95% CI, 2.0-10.1; P = .002). CONCLUSIONS: The results of this study uphold the current recommendations for hereditary breast and ovarian cancer screening of cancers other than breast and ovarian cancer by the National Comprehensive Cancer Network. Larger cohorts and collaborations are needed to further verify these findings.
Authors: Marcia Irene Canto; Ralph H Hruban; Elliot K Fishman; Ihab R Kamel; Richard Schulick; Zhe Zhang; Mark Topazian; Naoki Takahashi; Joel Fletcher; Gloria Petersen; Alison P Klein; Jennifer Axilbund; Constance Griffin; Sapna Syngal; John R Saltzman; Koenraad J Mortele; Jeffrey Lee; Eric Tamm; Raghunandan Vikram; Priya Bhosale; Daniel Margolis; James Farrell; Michael Goggins Journal: Gastroenterology Date: 2012-01-12 Impact factor: 22.682
Authors: C J van Asperen; R M Brohet; E J Meijers-Heijboer; N Hoogerbrugge; S Verhoef; H F A Vasen; M G E M Ausems; F H Menko; E B Gomez Garcia; J G M Klijn; F B L Hogervorst; J C van Houwelingen; L J van't Veer; M A Rookus; F E van Leeuwen Journal: J Med Genet Date: 2005-09 Impact factor: 6.318
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber Journal: J Natl Cancer Inst Date: 2002-09-18 Impact factor: 13.506
Authors: J Iqbal; A Ragone; J Lubinski; H T Lynch; P Moller; P Ghadirian; W D Foulkes; S Armel; A Eisen; S L Neuhausen; L Senter; C F Singer; P Ainsworth; C Kim-Sing; N Tung; E Friedman; M Llacuachaqui; S Ping; S A Narod Journal: Br J Cancer Date: 2012-10-25 Impact factor: 7.640
Authors: Danylo Rafhael Costa-Silva; Maria da Conceição Barros-Oliveira; Rafael Soares Borges; Larysse Maira Campos-Verdes; João Paulo da Silva-Sampaio; Carla Solange Escorcio-Dourado; Luana Mota Martins; Airlane Pereira Alencar; Edmund Chada Baracat; Vladimir Costa Silva; Benedito Borges da Silva Journal: Med Oncol Date: 2017-03-17 Impact factor: 3.064
Authors: Peter A Johansson; Vaishnavi Nathan; Lauren M Bourke; Jane M Palmer; Tongwu Zhang; Judith Symmons; Madeleine Howlie; Ann-Marie Patch; Jazlyn Read; Elizabeth A Holland; Helen Schmid; Sunil Warrier; William Glasson; Veronica Höiom; Karin Wadt; Göran Jönsson; Håkan Olsson; Christian Ingvar; Graham Mann; Kevin M Brown; Nicholas K Hayward; Antonia L Pritchard Journal: Melanoma Res Date: 2019-10 Impact factor: 3.599
Authors: Axel Muendlein; Bettina H Rohde; Klaus Gasser; Anton Haid; Stephanie Rauch; Elena Kinz; Heinz Drexel; Wera Hofmann; Verena Schindler; Rita Kapoor; Thomas Decker; Alois H Lang Journal: J Cancer Res Clin Oncol Date: 2015-05-15 Impact factor: 4.553